Bristol Myers Squibb EVP vests 51,172 RSUs
Bristol Myers Squibb executive Cristian Massacesi, EVP, Chief Medical Officer and Head of Development, reported the vesting and conversion of 51,172 restricted stock units into an equal number of common shares on August 1, 2026.
Rhea-AI Filing Summary
Bristol Myers Squibb executive Cristian Massacesi, EVP, Chief Medical Officer and Head of Development, reported the vesting and conversion of 51,172 restricted stock units into an equal number of common shares on August 1, 2026. To cover tax obligations, 26,175 shares were withheld at a per-share value of $65.31. Following the RSU conversion, Massacesi reported holding 153,519 restricted stock units, and these transactions were not designated as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
51,172 shares exercised/converted
Exercise
3 txns
Insider
Massacesi Cristian
Role
EVP,Chief Med Offr,Head of Dev
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F1 | 51,172 | $0.00 | $0.00 |
| Exercise | Common Stock, $0.10 par value F1 | 51,172 | $0.00 | $0.00 |
| Tax Withholding | Common Stock, $0.10 par value F2 | 26,175 | $65.31 | $1.71M |
Holdings After Transaction:
Restricted Stock Units — 153,519 contracts (Direct);
Common Stock, $0.10 par value — 24,997 shares (Direct)
Footnotes (3)
- F1. The restricted share units will vest in four equal annual installments on the first, second, third, and fourth anniversaries of the grant date.
- F2. Shares withheld for payment of taxes upon vesting of awards.
- F3. Each restricted stock unit converts into one share of common stock upon vesting.
Key Figures
RSUs Converted: 51,172 units
Common Shares Acquired: 51,172 shares
Shares Withheld for Taxes: 26,175 shares
+2 more
5 metrics
RSUs Converted
51,172 units
Restricted stock units converting into common stock on August 1, 2026
Common Shares Acquired
51,172 shares
Shares of common stock received upon RSU conversion
Shares Withheld for Taxes
26,175 shares
Common shares withheld to pay tax liability on vesting
Tax Withholding Price
$65.31 per share
Value used for shares withheld for tax obligations
RSUs Held After Transaction
153,519 units
Restricted stock units reported as held following the conversion event
Key Terms
Restricted Stock Units, tax-withholding disposition, Exercise or conversion of derivative security
3 terms
Restricted Stock Units financial
"The restricted share units will vest in four equal annual installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"Payment of tax liability by delivering or withholding securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Exercise or conversion of derivative security financial
"transaction code description "Exercise or conversion of derivative security""
FAQ
What equity transactions did Bristol Myers Squibb (BMY) EVP Cristian Massacesi report?
Cristian Massacesi reported 51,172 restricted stock units vesting and converting into an equal number of common shares on August 1, 2026. 26,175 shares were simultaneously withheld at $65.31 per share to satisfy tax obligations related to the vesting event.
How many restricted stock units vested and converted into Bristol Myers Squibb (BMY) common stock?
On August 1, 2026, 51,172 restricted stock units held by EVP Cristian Massacesi converted into 51,172 shares of Bristol Myers Squibb common stock. Each restricted stock unit converted into one share of common stock upon vesting, according to the reported terms.
What restricted stock unit holdings did Cristian Massacesi report after these BMY transactions?
After the August 1, 2026 transactions, Cristian Massacesi reported holding 153,519 restricted stock units. These units are scheduled to vest in four equal annual installments on the first through fourth anniversaries of the relevant grant date, based on the award terms described.
Were Cristian Massacesi’s reported BMY transactions under a Rule 10b5-1 trading plan?
The report indicates the transactions were not designated as being made under a Rule 10b5-1 trading plan, as the applicable checkbox for such plans was not marked. The activity instead reflects scheduled vesting, conversion of restricted stock units, and tax withholding.
What positions does Cristian Massacesi hold at Bristol Myers Squibb (BMY)?
Cristian Massacesi is reported as an Executive Vice President, serving as Chief Medical Officer and Head of Development at Bristol Myers Squibb. The equity transactions discussed relate to his compensation in the form of restricted stock unit awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
